Diary - News
All news Adocia announces positive topline results for the first clinical study of ADO09
Lyon, France, April 9th, 2019 – 6:00 pm CET - Adocia (Euronext Paris: FR0011184241 – ADOC) the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, announces today positive topline pharmacodynamic and safety results from the first Phase 1 study of ADO09, a ready-to-use, pH 4, co-formulation at fixed ratio of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog (“A21G human insulin”), a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine (Lantus®, Sanofi). A21G human insulin is considered to be safe, as millions of people using insulin glargine are routinely exposed to it1. ADO09 is an innovative formulation for which Adocia has filed an international patent application.